LLY

1,183.46

0.13% 1.57

시간 외 거래: 1183.56 0.10 +0.01%

일라이 릴리 (LLY)

개요 뉴스 가격 이력 옵션 체인 Financials LLY 왜 하락? 토론 예측 주식 분할 배당 이력

전일 마감가:

$1,181.89

열려 있는:

$1185.32

하루 거래량:

1.91M

Relative Volume:

0.73

시가총액:

$1.05T

수익:

$72.25B

순이익/손실:

$25.28B

주가수익비율:

42.60

EPS:

27.781

순현금흐름:

$10.37B

1주 성능:

+2.65%

1개월 성능:

-4.07%

6개월 성능:

+29.15%

1년 성능:

+65.61%

1일 변동 폭

$1,160.84

$1,190.00

1주일 범위

$1,134.41

$1,197.79

52주 변동 폭

$716.08

$1,292.65

일라이 릴리 Stock (LLY) Company Profile

명칭

Lilly Eli Co

부문

Healthcare (1067)

산업

Drug Manufacturers - General (20)

전화

(317) 276-2000

주소

LILLY CORPORATE CTR, INDIANAPOLIS, IN

직원

50,000

트위터

@LillyPad

다음 수익 날짜

2026-10-29

최신 SEC 제출 서류

LLY's Discussions on Twitter

Compare LLY vs JNJ, ABBV, MRK, NVS

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
LLY Lilly Eli Co	1,183.46	1.05T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	271.22	652.31B	97.93B	21.04B	17.80B	8.6278
ABBV Abbvie Inc	264.34	468.50B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	148.78	365.09B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	145.46	272.89B	54.66B	13.58B	16.05B	7.0171

일라이 릴리 Stock (LLY) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-03-17	다운그레이드	HSBC Securities	Hold → Reduce
2026-02-25	개시	RBC Capital Mkts	Outperform
2026-02-20	개시	Barclays	Overweight
2026-01-07	재개	UBS	Buy
2025-12-16	업그레이드	Daiwa Securities	Neutral → Buy
2025-12-15	재확인	BofA Securities	Buy
2025-12-15	재확인	Goldman	Buy
2025-11-13	개시	Scotiabank	Sector Outperform
2025-11-10	업그레이드	Leerink Partners	Market Perform → Outperform
2025-10-20	재확인	BMO Capital Markets	Outperform
2025-10-14	업그레이드	Erste Group	Hold → Buy
2025-09-17	다운그레이드	Berenberg	Buy → Hold
2025-08-27	업그레이드	HSBC Securities	Reduce → Hold
2025-08-18	다운그레이드	Daiwa Securities	Outperform → Neutral
2025-08-07	다운그레이드	Leerink Partners	Outperform → Market Perform
2025-06-05	다운그레이드	Erste Group	Buy → Hold
2025-04-28	다운그레이드	HSBC Securities	Buy → Reduce
2025-04-22	개시	Cantor Fitzgerald	Overweight
2024-12-10	재개	BofA Securities	Buy
2024-11-15	개시	Wolfe Research	Outperform
2024-10-17	개시	Bernstein	Outperform
2024-09-13	재개	Citigroup	Buy
2024-08-12	업그레이드	Deutsche Bank	Hold → Buy
2024-02-21	다운그레이드	DZ Bank	Buy → Hold
2024-02-16	재확인	Morgan Stanley	Overweight
2023-12-21	다운그레이드	Daiwa Securities	Buy → Outperform
2023-11-09	개시	Deutsche Bank	Hold
2023-10-20	재개	UBS	Buy
2023-08-09	업그레이드	Jefferies	Hold → Buy
2023-07-26	재확인	Citigroup	Buy
2023-07-14	개시	HSBC Securities	Buy
2023-05-24	재확인	BofA Securities	Buy
2023-05-24	재확인	UBS	Buy
2023-03-13	업그레이드	Wells Fargo	Equal Weight → Overweight
2023-03-06	개시	Jefferies	Hold
2023-02-15	다운그레이드	Societe Generale	Hold → Sell
2022-11-18	개시	Credit Suisse	Outperform
2022-09-22	업그레이드	UBS	Neutral → Buy
2022-05-23	개시	SVB Leerink	Outperform
2022-04-06	재개	Morgan Stanley	Overweight
2022-03-10	개시	Daiwa Securities	Outperform
2022-01-21	업그레이드	DZ Bank	Hold → Buy
2022-01-03	재확인	Bernstein	Mkt Perform
2021-12-17	개시	Goldman	Neutral
2021-12-16	재확인	BMO Capital Markets	Outperform
2021-12-16	재확인	BofA Securities	Buy
2021-12-09	재개	Wells Fargo	Equal Weight
2021-11-19	개시	BMO Capital Markets	Outperform
2021-10-11	업그레이드	Berenberg	Hold → Buy
2021-09-29	업그레이드	Citigroup	Neutral → Buy
2021-08-05	업그레이드	DZ Bank	Hold → Buy
2021-07-27	재개	Truist	Buy
2021-06-24	재확인	Cantor Fitzgerald	Overweight
2021-01-19	업그레이드	Mizuho	Neutral → Buy
2020-12-10	업그레이드	Wolfe Research	Peer Perform → Outperform
2020-11-10	재개	Bernstein	Mkt Perform
2020-09-29	개시	Berenberg	Hold
2020-09-03	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2020-06-16	업그레이드	Guggenheim	Neutral → Buy
2020-04-21	다운그레이드	UBS	Buy → Neutral
2020-04-09	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2020-02-06	개시	Mizuho	Neutral
2019-12-18	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2019-10-17	재개	BofA/Merrill	Buy
2019-05-28	개시	Goldman	Buy
2019-04-24	업그레이드	Edward Jones	Hold → Buy
2019-04-11	다운그레이드	Guggenheim	Buy → Neutral
2019-03-12	개시	JP Morgan	Overweight
2019-01-23	개시	UBS	Buy
2018-11-26	다운그레이드	Citigroup	Buy → Neutral
2018-10-31	업그레이드	Credit Suisse	Underperform → Neutral
2018-10-09	개시	Guggenheim	Buy
2018-10-01	재확인	SunTrust	Buy
2018-09-26	재개	JP Morgan	Overweight

모두보기

일라이 릴리 주식(LLY)의 최신 뉴스

06:20 AM

Eli Lilly (LLY) Gains FDA Nod for Olumiant in Pediatric Alopecia Areata - gurufocus.com

06:20 AM

01:16 AM

Eli Lilly stock closes at USD 1,181.89, up 2.68 percent at the closing bell - AD HOC NEWS

01:16 AM

01:14 AM

Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says - Reuters

01:14 AM

12:03 PM

Jury awards Nektar Therapeutics $90M in rezpeg dispute with Eli Lilly - Dealroom

11:17 AM

10:42 AM

Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury FundsEli Lilly (NYS - Benzinga

10:42 AM

09:17 AM

Eli Lilly stock gains 2.86 percent as guidance rises - AD HOC NEWS

09:17 AM

09:00 AM

Editorial: Lilly CEO calls on city, state to get serious about quality of life - Indianapolis Business Journal

09:00 AM

08:06 AM

Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly - Investing.com Canada

08:06 AM

06:05 AM

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? - The Motley Fool

06:05 AM

04:38 AM

FDA approves Lilly’s Onswik for type 2 diabetes in adults - yahoo.com

04:38 AM

04:03 AM

91-year-old investor sees healthcare titan doubling in 3 years - thestreet.com

04:03 AM

12:37 PM

Eli Lilly and Co. stock gains 3.51 percent ahead of the open - AD HOC NEWS

12:37 PM

Sep 24, 2026

Jurisdictional Skepticism Puts Eli Lilly Appeal On Thin Ice - Law360

Sep 24, 2026

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail

Sep 24, 2026

Eli Lilly Hit With $90M Verdict In Nektar's Rezpeg Breach Suit - Law360

Sep 24, 2026

Eli Lilly (LLY) Stock Is Up, What You Need To Know - Yahoo Finance Australia

Sep 24, 2026

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? - The Motley Fool

Sep 24, 2026

Eli Lilly & Co. stock outperforms competitors on strong trading day - MarketWatch

Sep 24, 2026

Medicare just handed Eli Lilly a massive weight-loss win - sg.finance.yahoo.com

Sep 24, 2026

Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact - MedCity News

Sep 24, 2026

FDA approves Eli Lilly's once-weekly insulin On... - Pluang

Sep 24, 2026

Eli Lilly and InnoCare sign drug discovery deal worth up to $3.35B - qz.com

Sep 24, 2026

Eli Lilly and Company (NYSE:LLY) Anchors Healthcare Focus on Deals and Clearances - Kalkine Media

Sep 24, 2026

Lilly Wins FDA Nod For Weekly Insulin, Signs $3.25 Billion InnoCare Pact - Benzinga

Sep 24, 2026

Lilly’s Ricks says state needs to emphasize quality of life, health care - dailyjournal.net

Sep 24, 2026

Lilly extends China innovation push in $3.35B Innocare deal - BioWorld News

Sep 24, 2026

FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes - Dealroom

Sep 24, 2026

InnoCare and Lilly ink deal worth up to $3.35 billion across five drug targets - The Pharma Letter

Sep 24, 2026

US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes - Reuters

Sep 24, 2026

Eli Lilly Rises After FDA Approval for Once-Weekly Diabetes Insulin - Quiver Quantitative

Sep 24, 2026

How Is Lilly (NYSE:LLY) Broadening Its S&P 500 Pipeline Today? - Kalkine Media

Sep 24, 2026

Healthcare is a great defensive sector to be in when the rest of the market is crapping in their pants! - Moomoo

Sep 24, 2026

Eli Lilly and Co Stock (LLY) Moved Up by 3.73% on Sep 24: A Full Analysis - TradingKey

Sep 24, 2026

InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly - Pharmaceutical Executive

Sep 24, 2026

Eli Lilly Stock Price Today (LLY) | NYSE - TechGraph

Sep 24, 2026

Governor Abbott Delivers Remarks At Lilly Groundbreaking In Houston - Texas Border Business

Sep 24, 2026

Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare - pharmaceutical-technology.com

Sep 24, 2026

LLY Looks 26.0% Undervalued on GF Value™ After FDA Approval of O - GuruFocus

Sep 24, 2026

Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal - pmlive.com

Sep 24, 2026

LLY Looks 26.0% Undervalued on GF Value™ After FDA Approval of W - GuruFocus

Sep 24, 2026

Eli Lilly signs deal worth up to USD 3.35bn with China's InnoCare - medwatch.com

Sep 24, 2026

U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes - Eli Lilly

Sep 24, 2026

Lilly's FDA-approved weekly insulin could mean over 300 fewer shots a year than daily insulin - Stock Titan

Sep 24, 2026

InnoCare and Eli Lilly strike research collaboration worth up to $3.35B - Dealroom

Sep 24, 2026

InnoCare Pharma partners with Eli Lilly in drug research deal - chinadaily.com.cn

Sep 24, 2026

InnoCare Pharma Partners with Eli Lilly on New Drug Development, Potential Milestones Up to $3.25 Billion - finance.biggo.com

Sep 24, 2026

Lilly reaches $3.35B deal with China's InnoCare - Breakingthenews.net

Sep 24, 2026